NFKB1 and atherosclerosis: The rationale for this strategy draws back to the concept that pathological CAM expression during vascular inflammation is induced by the inflammatory gene expression programme encoded by innate immunity.103 Several regulatory molecules inherent to this response have been considered as potential therapeutic targets for treating inflammation, including cytokines, transcriptional regulators, and protein machinery.104 One of the most extensively studied of these in the context of atherosclerosis is the pro-inflammatory nuclear factor-κB (NF-κB) master regulator.